BBIO
BBIO
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$55K
Insider Sales
73
$869.30M
Total Volume
$869.36M
75 transactions
Net Activity
$869.25M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Kkr Genetic Disorder L.P.
10%
$402.96M total
Viking Global Investors LP
10%
$260.99M total
Kumar Neil
CEO
$108.83M total
Cook Jennifer E.
Dir
$21.92M total
McCormick Frank
Dir
$21.67M total
Quick Actions
BBIO has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. BBIO ranks #452 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at BBIO (BBIO) engaged in a total of 75 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 73 were sales. The total volume of insider trading reached $869.36M.
The net insider activity for BBIO shows a net selling bias of $869.25M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Kkr Genetic Disorder L.P. (10%), who traded 6.00M shares valued at $205.20M on May 12, 2025.
BridgeBio Pharma, Inc. (BBIO) stock price, news, quote and history
BridgeBio Pharma, Inc. (BBIO) Stock Price, News, Quote & History
BBIO: Director Neil Kumar proposes sale of 34,980 BridgeBio shares
A family trust proposes selling 30,000 BridgeBio Pharma (BBIO) shares around Nov. 19, 2026.
Palisade Bio Stock Price Forecast. Should You Buy PALI?
Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs
FAQs About BBIO Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for BBIO.